Drugmakers Biogen and Eisai have achieved successful results with regards to their long-awaited experimental drug for Alzheimer’s patients, called the BAN-2401, which were presented at Chicago’s Alzheimer’s Association International Conference. This test might potentially open up newer avenues in the Alzheimer’s drug researches. However, Eisai was unable to answer some of the doctor’s queries regarding additional data for the drug in the ensuing press conference, which may point to exercising cautious optimism for doctors with regards to the drug.
According to the tests, there were 161 patients receiving the best doses, who experienced a decline of less than 30% during 18 months using a cognitive function scale, as opposed to the placebo group’s 247 patients. The results obtained were significantly better than the expectations of the financial analysts. The patients receiving the largest dose of 10 mg/kg drug infusions biweekly, showed a significantly lower decline statistically as opposed to the placebo groups at six and twelve months too. This was on the basis of ADCOMS measure that was used during the trial; however, doctors are in the dark with regards to this new scale. Patients with the highest dose displayed a vast difference statistically from placebo group, with 47% lower decline in 18 months, based on ADAS-cog scale. This difference was significant statistically at 6 months as well, however, not at 12 months. There was, however, not much difference between these treatment groups on CDR-SB scale. According to David Knopman, the spokesperson with the Alzheimer’s Association, there will be a lengthier Phase-3 study following this test phase.
Meanwhile, an Australian short movie showing the positive effects of the use of technology on people suffering from dementia as well as their carers has been added as part of a global awareness campaign regarding the condition. The 5-minute short features Australia’s path-breaking innovations in interactive 3D games, virtual reality as well as immersive training experiences. The movies consist of dementia-afflicted people and their carers talking about their experiences with the technologies. The campaign, known as #Every3Seconds, was formed by Alzheimer’s Disease International and launched at their Chicago conference, referring to the fact that every three seconds, one person in the world is afflicted with dementia.